Developing an effective glycoconjugate vaccine against Group A Streptococcus causing rheumatic fever/heart disease

点击翻译按钮获取中文摘要

Globally Australian Aboriginal and Torres Strait Islanders have the highest recorded rate of Group A Streptococcus (GAS) infection, mainly rheumatic heart disease and rheumatic fever. GAS infection is endemic and often fatal due to post-infection problems.This project aims to develop a glycoconjugate vaccine to prevent GAS infection.We aim to avert these deaths by making a vaccine from small, specific parts of GAS proteins so the body makes safe antibodies that stop GAS and its related diseases.